Jing Wang

Dr. Jing Wang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
JWJing Wang
Jing Wang
QWQiheng Wan
Qiheng Wan
ZHZehan Huang
Zehan Huang
HYHUANG Yu-qing
HUANG Yu-qing
BZBin Zhang
Bin Zhang
SWSong Wen
Song Wen
Background: Lipoprotein(a) [Lp(a)] is a genetically determined, atherogenic, and prothrombotic lipoprotein. However, its prognostic value in patients who undergo successful chronic total occlusion (CTO) percutaneous coronary intervention (PCI) remains undefined. Methods: This single-center retrospective cohort study included 1509 patients who underwent successful CTO PCI. The primary outcome was cardiovascular death; secondary outcome was major adverse cardiovascular events (MACEs, cardiovascular death or nonfatal myocardial infarction). Multivariable Cox regression and restricted cubic splines (RCS) assessed the association between Lp(a) and outcomes. Results: Over median follow-up of 810 days, 53 (3.5%) cardiovascular deaths and 62 (4.1%) MACEs occurred. Each 1-SD increase in log-transformed Lp(a) was associated with a 51% higher risk of cardiovascular death (aHR 1.51, 95% CI 1.11–2.05, p = 0.008) and a 44% higher risk of MACEs (aHR 1.44, 95% CI 1.09–1.91, p = 0.011). Compared with Lp(a) < 30 mg/dL, Lp(a) ≥ 50 mg/dL conferred a 2.07-fold higher risk of cardiovascular death (95% CI 1.07–4.00, p = 0.029) and a 1.94-fold higher risk of MACEs (95% CI 1.07–3.53, p = 0.030). RCS analysis demonstrated a linear dose–response relationship between log-transformed Lp(a) and both cardiovascular death (p for nonlinearity = 0.653) and MACEs (p for nonlinearity = 0.562). The association was modified by age, hypertension, and left ventricular ejection fraction and remained robust in sensitivity analyses. Conclusions: In patients undergoing successful CTO PCI, elevated Lp(a) was independently and linearly associated with higher risks of cardiovascular death and MACEs. These findings suggest that Lp(a) may serve as a useful prognostic marker to enhance risk stratification in this high-risk population. Large-scale prospective cohorts are needed to validate these findings before clinical translation can be considered.

10 September 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
SWSong Wen
Song Wen
ZHZehan Huang
Zehan Huang
LMLingbing Meng
Lingbing Meng
QWQiheng Wan
Qiheng Wan
XHXingjie Huang
Xingjie Huang
JWJing Wang
Jing Wang
Background: Even after technically successful percutaneous coronary intervention (PCI) for chronic total occlusion (CTO), patients face persistent excess cardiovascular risk. The hemoglobin glycation index (HGI), a marker of interindividual glycation heterogeneity, has not been studied in this setting. Methods: We enrolled 1, 513 patients who had undergone successful CTO-PCI between 2011 and 2023 at Guangdong Provincial People’s Hospital. HGI was computed as the difference between the measured HbA1c and the value predicted from fasting plasma glucose using a cohort-derived linear equation. The primary composite outcome included cardiovascular death, non-fatal myocardial infarction, and stroke (cardiovascular events, CVEs). Secondary outcomes were all-cause and cardiovascular death. Multivariable Cox regression and restricted cubic splines were applied to assess associations. Results: During a median 810-day follow-up, 83 (5.5%) all-cause deaths, 53 (3.5%) cardiovascular deaths, and 73 (4.8%) CVEs occurred. After full adjustment, Each 1-standard deviation increment in HGI conferred an independent hazard of 1.34 (95% CI 1.14–1.58) for all-cause mortality, 1.52 (95% CI 1.25–1.83) for cardiovascular mortality, and 1.42 (95% CI 1.15–1.61) for CVEs. Compared with the lowest tertile, patients in the highest HGI tertile exhibited a 2.41-fold (95% CI 1.37–4.25, P = 0.002), 4.13-fold (95% CI 1.91–8.94, P<0.001), and 2.73-fold (95% CI 1.47–5.07, P = 0.001) higher risk of all-cause mortality, cardiovascular mortality, and CVEs, respectively. RCS analysis revealed a linear dose-response relationship, with a secondary exploratory threshold effect identified at HGI = –0.15 for CVEs (HR 2.05, 95% CI 1.22–3.44). Conclusions: In this retrospective cohort study, elevated HGI was independently and linearly associated with heightened long-term adverse clinical outcomes after successful CTO-PCI. These findings suggest that HGI may have potential as a prognostic marker for risk stratification in this population; however, prospective validation is required before clinical application.